# Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

> **NCT04483960** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Melbourne** · enrollment: 2200 (estimated)

## Conditions studied

- SARS-CoV-2 Infection (COVID-19)

## Interventions

- **DRUG:** (Arm Closed) Nafamostat Mesilate
- **DRUG:** (Arm Closed) Enoxaparin
- **DRUG:** (Arm Closed) Dalteparin
- **DRUG:** (Arm Closed) Tinzaparin
- **BIOLOGICAL:** (Arm Never Opened) Hyperimmune globulin
- **DRUG:** Nirmatrelvir-Ritonavir
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT04483960
- **Lead sponsor:** University of Melbourne
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-28
- **Primary completion:** 2025-07-25
- **Final completion:** 2025-12-31
- **Target enrollment:** 2200 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483960, "Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04483960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*